Characterization of a thermostable Cas13 enzyme for one-pot detection of SARS-CoV-2

Ahmed Mahas, Tin Maršić, Mauricio Lopez-Portillo Masson, Qiaochu Wang, Rashid Aman, Cheng Zheng, Zahir Ali, Madain S. Alsanea, Ahmed A. Al‐Qahtani, Bernard Ghanem, Fatimah S. Alhamlan, Magdy M. MahfouzProceedings of the National Academy of Sciences 2022 · DOI

TL;DR

Researchers have engineered a thermostable CRISPR-Cas13 enzyme (TccCas13a) that functions optimally at higher temperatures, enabling a robust, one-pot diagnostic assay (OPTIMA-dx) for SARS-CoV-2. This assay is sensitive, specific, and compatible with rapid sample processing, making it suitable for point-of-care applications and even multiplexed detection.

What Problem Does This Paper Address?

Current CRISPR-Cas13 diagnostic systems, while powerful for nucleic acid detection, typically operate at mesophilic temperatures (~37°C). This limitation creates a mismatch with isothermal amplification methods like RT-LAMP, which require higher temperatures (55-65°C) for optimal performance. This necessitates multi-step, two-pot assays, increasing the risk of contamination and complicating point-of-care (POC) implementation. The paper addresses this by identifying and characterizing a thermostable Cas13 ortholog that can function across a broad temperature range, bridging the gap between amplification and detection for a streamlined, one-pot diagnostic.

Methods

The core of this work involves the identification and characterization of a novel thermostable Cas13 enzyme, TccCas13a, from the thermophilic bacterium Thermoclostridium caenicola. Key methods include:

  • Phylogenetic Analysis: To identify potential thermophilic Cas13 candidates.
  • Protein Expression and Purification: Standard recombinant protein production in E. coli.
  • Differential Scanning Fluorimetry (DSF): To assess protein melting points and thermostability.
  • SDS-PAGE: To evaluate protein stability under various temperature conditions.
  • In Vitro Catalytic Assays: To measure both cis (self-cleavage) and trans (collateral) RNase activities of TccCas13a and a related thermophilic ortholog, HheCas13a, across a range of temperatures.
  • CRISPR-Cas13 Sequence Requirement Studies: Investigating the impact of crRNA spacer length and mismatches on TccCas13a activity.
  • Pre-crRNA Processing Assays: To determine if TccCas13a, unlike some mesophilic Cas13s, can process its own precursor RNA.
  • Enzyme Kinetics: Michaelis-Menten analysis to quantify the catalytic efficiency of TccCas13a.
  • One-Pot RT-LAMP-Cas13 Assay Development (OPTIMA-dx): Coupling RT-LAMP for RNA amplification with TccCas13a-based detection in a single tube and at a single temperature (56°C). This involved designing primers with T7 promoter sequences for in vitro transcription of LAMP products.
  • Multiplexed Detection: Combining TccCas13a with a thermostable Cas12b enzyme (AapCas12b) to detect multiple targets (SARS-CoV-2 and RNase P) simultaneously using different fluorescent reporters.
  • Mobile Application Development: Creating a deep learning-based smartphone app for automated data collection and interpretation of OPTIMA-dx results.
  • Clinical Validation: Testing the assay on patient samples and comparing results with qRT-PCR.
  • Sample Preparation Optimization: Developing a rapid, extraction-free protocol for sample lysis and concentration.

Datasets

  • Synthetic SARS-CoV-2 Genome: Used for determining the limit of detection (LoD) of the OPTIMA-dx assay.
  • Clinical Samples:
    • 73 qRT-PCR-positive and 27 qRT-PCR-negative samples from patients with COVID-19 were used for clinical validation of OPTIMA-dx.
  • 45 randomized samples (40 positive, 5 negative) were used for further validation.
  • 16 oropharyngeal swabs from patients with COVID-19 and 2 negative swabs were used for validating multiplexed detection with the quick extraction method.
  • Samples spiked with noninfectious SARS-CoV-2 virus particles were used to test the extraction protocol.
  • Other Human Viruses: SARS-CoV-1, MERS-CoV, H1N1, HCoV-OC43, HCoV-229E, and HCoV-NL63 were used to assess the specificity of OPTIMA-dx.
  • HCV and TYLCV: In vitro-transcribed RNAs of two common HCV genotypes and TYLCV ssDNA virus were used to demonstrate the versatility of OPTIMA-dx for other pathogens.

No new benchmarks were explicitly introduced, but the study validates OPTIMA-dx against the established gold standard, qRT-PCR.

Key Insights and Ideas

  • Thermostable Cas13 is a Game Changer for One-Pot Diagnostics: The identification of TccCas13a, which functions effectively at temperatures compatible with RT-LAMP, is a critical step towards truly integrated, single-tube diagnostic assays. This overcomes a major hurdle in current CRISPR-based diagnostics.
  • TccCas13a's Unique Properties: TccCas13a exhibits robust cis and trans activity over a broad temperature range (37-70°C) and, interestingly, appears to be defective in precrRNA processing, similar to its close thermophilic relative HheCas13a. This suggests a potential link between thermostability and the lack of precrRNA processing.
  • OPTIMA-dx: A Streamlined Diagnostic: The development of OPTIMA-dx demonstrates the power of combining thermostable Cas13 with RT-LAMP for a rapid, sensitive, and specific one-pot assay for SARS-CoV-2. The assay's compatibility with simple extraction methods and visual readout further enhances its POC potential.
  • Multiplexing is Achievable: The successful integration of TccCas13a with a thermostable Cas12b enzyme (AapCas12b) for multiplexed detection highlights the potential for simultaneous detection of multiple targets, significantly increasing diagnostic throughput and utility.
  • Smartphone Integration for Accessibility: The development of a mobile app for data interpretation and sharing democratizes access to diagnostic results, especially in resource-limited settings.

Key Results

  • TccCas13a Activity: TccCas13a exhibits robust cis and trans catalytic activities across a broad temperature range of 37 to 70°C.
  • OPTIMA-dx Sensitivity: The assay achieved a limit of detection (LoD) of 10 copies/µL for synthetic SARS-CoV-2 RNA.
  • OPTIMA-dx Specificity: OPTIMA-dx showed no cross-reactivity with other tested human viruses.
  • Clinical Validation: OPTIMA-dx demonstrated 94.5% sensitivity and 100% specificity when tested on clinical samples, with high concordance to qRT-PCR. The assay could detect samples with Ct values up to 34.
  • Multiplexed Detection: The multiplexed OPTIMA-dx assay successfully detected both SARS-CoV-2 and the RNase P internal control in clinical samples.
  • Rapid Detection: The OPTIMA-dx assay provided results within 45-60 minutes.
  • Extraction-Free Protocol: A rapid, extraction-free sample processing method was developed, compatible with OPTIMA-dx.

Limitations and Future Work

  • Pre-crRNA Processing Defect: The inability of TccCas13a and HheCas13a to process precrRNAs is noted as a unique characteristic, potentially linked to their thermostability. Further structural studies are suggested to elucidate this mechanism.
  • HheCas13a One-Pot Performance: While HheCas13a showed good performance in two-pot assays, its one-pot performance was not significant. Future work could focus on optimizing HheCas13a for one-pot applications.
  • Freeze-Drying Optimization: While reagents were successfully lyophilized, further optimization is needed to enhance reaction speed and performance after freeze-drying.
  • Simple Extraction for POC: The authors suggest that future work could focus on developing even simpler extraction methods that integrate lysis and detection into a single step.
  • Broader Applications: The thermostable Cas13 enzymes are envisioned for applications beyond diagnostics, including RNA knockdown, editing, imaging, and virus interference, particularly in industrially relevant thermophiles.
  • Multiplexed Visual Readout: Future work will include developing a visual readout for multiplexed detection reactions for simpler POC applications.

Summary updated

Abstract

Type VI CRISPR-Cas systems have been repurposed for various applications such as gene knockdown, viral interference, and diagnostics. However, the identification and characterization of thermophilic orthologs will expand and unlock the potential of diverse biotechnological applications. Herein, we identified and characterized a thermostable ortholog of the Cas13a family from the thermophilic organism <i>Thermoclostridium caenicola</i> (TccCas13a). We show that TccCas13a has a close phylogenetic relation to the HheCas13a ortholog from the thermophilic bacterium <i>Herbinix hemicellulosilytica</i> and shares several properties such as thermostability and inability to process its own pre-CRISPR RNA. We demonstrate that TccCas13a possesses robust <i>cis</i> and <i>trans</i> activities at a broad temperature range of 37 to 70 °C, compared with HheCas13a, which has a more limited range and lower activity. We harnessed TccCas13a thermostability to develop a sensitive, robust, rapid, and one-pot assay, named OPTIMA-dx, for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. OPTIMA-dx exhibits no cross-reactivity with other viruses and a limit of detection of 10 copies/μL when using a synthetic SARS-CoV-2 genome. We used OPTIMA-dx for SARS-CoV-2 detection in clinical samples, and our assay showed 95% sensitivity and 100% specificity compared with qRT-PCR. Furthermore, we demonstrated that OPTIMA-dx is suitable for multiplexed detection and is compatible with the quick extraction protocol. OPTIMA-dx exhibits critical features that enable its use at point of care (POC). Therefore, we developed a mobile phone application to facilitate OPTIMA-dx data collection and sharing of patient sample results. This work demonstrates the power of CRISPR-Cas13 thermostable enzymes in enabling key applications in one-pot POC diagnostics and potentially in transcriptome engineering, editing, and therapies.
BibTeX
@inproceedings{mahas2022characterization,
  author = {Ahmed Mahas and Tin Maršić and Mauricio Lopez-Portillo Masson and Qiaochu Wang and Rashid Aman and Cheng Zheng and Zahir Ali and Madain S. Alsanea and Ahmed A. Al‐Qahtani and Bernard Ghanem and Fatimah S. Alhamlan and Magdy M. Mahfouz},
  title = {{Characterization of a thermostable Cas13 enzyme for one-pot detection of SARS-CoV-2}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2022},
  doi = {10.1073/pnas.2118260119},
}
Figure